danaher Archives - Medical Design Sourcing

Danaher grows profits 24% in Q4

Danaher (NYSE:DHR) this week posted fourth-quarter results that beat the overall consensus on Wall Street.

The Washington, D.C.-based company reported profits of $2.2 billion, or $2.99 per share, on sales of $8.4 billion for the three months ended Dec. 31, 2022, for a bottom-line gain of 24.8% on sales growth of 2.7% compared with Q4 2021.

Earnings per share were 45¢ ahead of The Street, where analysts were looking for sales of $7.9 billion.

“2022 was another great year for Danaher. Broad-based strength across the portfolio helped us deliver nearly 10% core revenue growth and double-digit earnings per share growth. Our team executed well in a challenging operating environment, enabling us to expand operating margins and generate strong cash flows. We believe this strong execution, paired with our investments in innovation drove market share gains in many of our businesses,” President and CEO Rainer Blair said in a news release.

“Looking ahead, we …

Danaher beats The Street in Q3

Danaher (NYSE:DHR) shares dipped today despite third-quarter results that came in well ahead of the consensus forecast.

The Washington, D.C.-based company posted profits of $1.6 billion, or $2.10 per share, on sales of $7.7 billion for the three months ended Sept. 30, 2022, for a 35.8% bottom-line gain on sales growth of 6%.

Adjusted to exclude one-time items, earnings per share were $2.56, 30¢ ahead of Wall Street, where analysts were looking for sales of $7.2 billion.

“We are pleased with our third quarter performance,” said Danaher president and CEO Rainer Blair. “The team maintained strong momentum in a challenging operating environment to deliver double-digit core revenue growth and solid margin expansion, earnings growth and cash flow generation. Our growth was broad-based across all three segments, a testament to the durability and attractive end-market positioning of the franchises that comprise Danaher.

“As we look ahead, we b…

Danaher rises on Street-beating Q2

Danaher (NYSE:DHR) shares got a boost today on second-quarter results that came in well ahead of the consensus forecast.

Shares of DHR were up 7.7% at $275.61 per share in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 1.3%.

The Washington, D.C.-based company posted profits of $1.7 billion, or $2.25 per share, on sales of $7.8 million for the three months ended July 1, 2022, for a 4.9% bottom-line slide on sales growth of 7.4%.

Adjusted to exclude one-time items, earnings per share were $2.76, 41¢ ahead of Wall Street, where analysts were looking for sales of $7.3 billion.

“We are pleased with our strong start to 2022,” Danaher President and CEO Rainer M. Blair said in a news release. “Our teams executed well in a challenging environment to deliver high-single-digit core revenue growth, double-digit adjusted earnings per share …

Danaher beats The Street in Q1

Danaher (NYSE:DHR) shares dipped slightly today on first-quarter results that came in ahead of the consensus forecast.

The Washington, D.C.-based company posted profits of $1.7 billion, or $2.31 per share, on sales of $7.7 billion for the three months ended April 1, 2022, for a 1.3% bottom-line gain on sales growth of 12.1%.

Adjusted to exclude one-time items, earnings per share were $2.76, 10¢ ahead of Wall Street, where analysts were looking for sales of $7.5 billion.

“We had a good start to the year with results exceeding our initial expectations,” Danaher President and CEO Rainer M. Blair said in a news release. “Our team successfully navigated a dynamic environment to deliver double-digit core revenue growth, approximately 10% adjusted earnings per share growth and $2.0 billion of operating cash flow, despite difficult prior-year comparisons.

“This performance was broad-based with all three of our segments delivering high-si…

How medtech fared in the first waves of the pandemic

[Photo by Martin Sanchez on Unsplash]Medtech industry revenue, research spending and employment declined in the first year of the COVID-19 pandemic, according to a Medical Design & Outsourcing analysis of financial data.

Total sales, R&D spending and employment for the world’s largest medical device companies declined in 2020 and early 2021, according to a Medical Design & Outsourcing analysis tallying the ongoing pandemic’s initial toll on the industry.

To compare performance before and during the pandemic, MDO used the financial data that we’ve historically gathered to rank our Big 100 companies in the last three years. The majority of these companies reported full-year results for 2020; others operate on a fiscal year and reported annual results in the first half of 2021.

Some companies are not in this year’s Big 100 but were included in the analysis because they were ranked in pre-pandemic years. The handful of companies that joined this yea…

How medtech fared in the first waves of the pandemic

[Photo by Martin Sanchez on Unsplash]

Medtech industry revenue, research spending and employment declined in the first year of the COVID-19 pandemic, according to a Medical Design & Outsourcing analysis of financial data.

Total sales, R&D spending and employment for the world’s largest medical device companies declined in 2020 and early 2021, according to a Medical Design & Outsourcing analysis tallying the ongoing pandemic’s initial toll on the industry.

To compare performance before and during the pandemic, MDO used the financial data that we’ve historically gathered to rank our Big 100 companies in the last three years. The majority of these companies reported full-year results for 2020; others operate on a fiscal year and reported annual results in the first half of 2021.

Some companies are not in this year’s Big 100 but were included in the analysis because they were ranked in pre…

The 100 largest medical device companies in the world

Nearly half a trillion dollars — $421 billion to be exact — that’s how much the world’s 100 largest medical device companies brought in over the past year amid the COVID-19 pandemic.

That’s one of the big takeaways from the Big 100, MassDevice and Medical Design & Outsourcing‘s annual analysis of the worlds’ 100 largest medtech companies. (Check out the full Big 100 rankings here.)

Aggregate revenue for approximately 100 of the largest medical technology companies dropped 1.2% in 2020 compared to 2019. But that’s not bad considering that the worst pandemic in a century was taking place, sparking a global recession in its wake.

Some medtech businesses that played critical roles fighting the pandemic — such as 3M’s Health Care segment and Hologic — even saw revenues increase and rose in the Big 100 rankings as a result.

Check out the full Big 100 rankings here>>

The 100 largest medical device companies in the world

Nearly half a trillion dollars — $421 billion to be exact — that’s how much the world’s 100 largest medical device companies brought in over the past year amid the COVID-19 pandemic.

That’s one of the big takeaways from the Big 100, MassDevice and Medical Design & Outsourcing‘s annual analysis of the worlds’ 100 largest medtech companies. (Check out the full Big 100 rankings here.)

Aggregate revenue for approximately 100 of the largest medical technology companies dropped 1.2% in 2020 compared to 2019. But that’s not bad considering that the worst pandemic in a century was taking place, sparking a global recession in its wake.

Some medtech businesses that played critical roles fighting the pandemic — such as 3M’s Health Care segment and Hologic — even saw revenues increase and rose in the Big 100 rankings as a result.

Check out the full Big 100 rankings here>>

Medtech M&A: The industry’s biggest mergers and acquisitions of 2021

[Image from Jp Valery on Unsplash]

Across 2021, medtech has seen a wide range of mergers and acquisitions covering several areas of devices, pharmaceuticals and more.

Some have gone off without a hitch, while others fell into serious scrutiny as mouthwatering financial figures were revealed and major technologies were acquired.

Here are the 10 biggest mergers and acquisitions in medtech in 2021:

Next>>

Danaher slides despite Street-beating Q3

Danaher (NYSE:DHR) shares dipped today even as the company registered third-quarter results that topped the consensus forecast.

The Washington, D.C.-based company posted profits of $1.2 billion, or $1.54 per share, on sales of $7.2 billion for the three months ended Sept. 30, 2021, for a 31.1% bottom-line gain on sales growth of 22.9%.

Adjusted to exclude one-time items, earnings per share were $2.39, 24¢ ahead of Wall Street, where analysts were looking for sales of $7 billion.

“Our team delivered another outstanding result in the third quarter, with over 20% core revenue growth and terrific earnings and cash flow performance. We continued to invest for growth across our businesses, expanding production capacity and accelerating innovation initiatives,” Danaher President & CEO Rainer M. Blair said in a news release. “Additionally, the recently closed acquisition of Aldevron enhances our portfolio and expands our capabilities into …

Women researchers receive a fraction of funding from the world’s biggest medtech companies

The gender divide in medtech extends beyond leadership and into funding for investigational studies by U.S. physicians.

Only 6.7% of physicians who received research payments from the world’s largest medical device companies in 2020 were women, according to an analysis of Medical Design & Outsourcing’s Big 100 list of medtech companies and CMS Open Payments data.

Among the 20 medical device companies that fund research by U.S. physicians are 3M, Abbott, BD, Boston Scientific, Johnson & Johnson (dba J&J Surgical Vision and J&J Vision Care), Medtronic (dba Medtronic, Medtronic Minimed, Medtronic USA, Medtronic Vascular), Royal Philips (dba Philips Electronics), Stryker and Zimmer Biomet.

Together, those companies paid $3.9 million to 312 doctors in 2020, but only 21 were women, receiving a collective $402,600.

Women physicians, on average, received 15.7% of payments from each of the top medtech companies, but accounted f…

Danaher announces executive changes

Danaher (NYSE:DHR) yesterday announced a number of personnel moves among executives at the company.

SVP & chief accounting officer Robert S. Lutz notified the company that he will step down from his position as of Jan. 1, 2022, with Cristopher M. Bouda set to succeed him. Bouda has served as Danaher’s VP of finance since joining in August 2016.

According to a news release, after his departure from the roles on Jan. 1, 2022, Lutz is expected to continue performing services to Danaher on a part-time basis.

In connection with Bouda’s promotion, his annual base salary will increase to $475,000 with a 2022 annual cash incentive compensation award opportunity under the company’s 2007 Omnibus Incentive Plan based on a target percentage of 60%. Bouda will also receive a 2022 annual equity award under the plan with a target award value of $500,000, split evenly between stock options and time-vested restricted stock units.

Additionally…